Matinas BioPharma Announces Collaboration with National Resilience to Explore and Evaluate Novel LNC Platform Delivery Technology for Certain Nucleic Acids
12 janv. 2023 07h00 HE
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids...
Matinas BioPharma Reports Third Quarter 2022 Financial Results and Highlights Recent Progress
02 nov. 2022 16h02 HE
|
Matinas BioPharma Holdings, Inc.
EnACT Phase 2 study of MAT2203 in cryptococcal meningitis met its primary endpoint with 95% two-week patient survival in the Cohort 4 all-oral regimen Phase 3 pivotal trial of MAT2203 for treatment...
Matinas BioPharma to Present at the ThinkEquity Annual Global Investment Conference
21 oct. 2022 07h00 HE
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., Oct. 21, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of nucleic acids...
Matinas BioPharma to Present New MAT2203 (Oral Amphotericin B) Data During IDWeek 2022
12 oct. 2022 07h00 HE
|
Matinas BioPharma Holdings, Inc.
Interim data from all-oral Cohort 4 of the EnACT Trial of MAT2203 in Cryptococcal Meningitis to be revealed along with an overview of the entire Phase 2 trial Late-breaking data demonstrate that...
BioNTech und Matinas BioPharma geben exklusive Forschungskollaboration zur Entwicklung neuer Formulierungen für mRNA-basierte Impfstoffe bekannt
11 avr. 2022 07h00 HE
|
BioNTech SE
Exklusive Forschungskollaboration kombiniert BioNTech’s Expertise in der Entwicklung mRNA-basierter Impfstoffe mit Matinas Lipid-Nanokristall (LNC)-Plattformtechnologie zur Entwicklung...
BioNTech and Matinas BioPharma Announce Exclusive Research Collaboration to Evaluate Novel Delivery Technology for mRNA-based Vaccines
11 avr. 2022 07h00 HE
|
BioNTech SE
Exclusive collaboration combines BioNTech’s mRNA vaccine development expertise and Matinas’ Lipid Nanocrystal (LNC) Delivery Platform Technology to advance novel formulations for mRNA vaccines,...